186 filings
Page 5 of 10
8-K
vnmuymyi2avxakh
6 May 22
Submission of Matters to a Vote of Security Holders
4:12pm
EFFECT
pnty3ke0
27 Apr 22
Notice of effectiveness
12:15am
424B5
3pd1320 5y
26 Apr 22
Prospectus supplement for primary offering
5:21pm
CORRESP
6mngebqu9 trc87xf
22 Apr 22
Correspondence with SEC
12:00am
8-K
02kud5lq3ecfl6y9 zmb
18 Apr 22
Regulation FD Disclosure
8:07am
UPLOAD
9nwokn
18 Apr 22
Letter from SEC
12:00am
S-3
cm44q5 nqwo
14 Apr 22
Shelf registration
4:56pm
8-K
ocwwh
14 Apr 22
Entry into a Material Definitive Agreement
4:02pm
8-K
jalpi2o
5 Apr 22
Regulation FD Disclosure
4:07pm
DEFA14A
b1y2i8nwrx8qs g4ixly
29 Mar 22
Additional proxy soliciting materials
4:15pm
8-K
7bzaknlkpah5d
14 Mar 22
Interim results demonstrate approximately 70% decreased risk of death for participants who entered the RESCUE-ALS long-term open label extension
7:02am
8-K
ecntwh6sa0ffbw
11 Mar 22
Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights
7:04am
8-K
brekv
24 Feb 22
Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022
7:02am
8-K
2t731appe3fbb8lzqlh
15 Feb 22
Clene Nanomedicine Provides Clinical Program Update
7:01am
8-K
1o3 wsta017wsp
2 Feb 22
Clene Announces New Chief Financial Officer Morgan Brown
12:00am
424B3
qaitngwavue5e7
18 Jan 22
Prospectus supplement
4:07pm
8-K
tu5ze8o2ghsbjch
18 Jan 22
Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial
7:00am
EFFECT
643po
14 Jan 22
Notice of effectiveness
12:15am